January 30, 2017
Another USA laswusit against Teva, Aralez charges for 4 patent infringements
Aralez Pharmaceuticals will press charges against Teva in the USA for infringing four patents.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 30, 2017
Drugmaker Novo Nordisk bets $145 million on post-Brexit UK science
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
January 30, 2017
Realm Therapeutics asks FDA’s approval for its first IND for atopic dermatitis treatment
Realm Therapeutics has submitted its first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR022, as a novel treatment for atopic dermatitis (AD).
January 28, 2017
Swedish Vicore Pharma’s IPF candidate C21 becomes orphan drug in US
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.
January 27, 2017
UPDATE: Lilly breaks up partnership deal with Adocia on diabetes BC Lispro study
UPDATE contains comment from Lilly
Eli Lilly has quit from a research and licence agreement with a Paris-listed clinical stage pharmaceutical company Adocia, the French company said on Friday.
January 27, 2017
Roche cancer drug taking bite out of Bristol’s Opdivo
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
January 27, 2017
AbbVie’s fourth quarter earnings down, but generates $809M more than 2015 full year
The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since becoming an independent company in 2013.
January 27, 2017
French Poxel exectedly falls short on revenue in Q4 2016
French drugmaker focused on diabetes treatments Poxel, said it expectedly did not generate meaningful revenues in the fourth quarter of 2016, but it is on track for developing two of its programs.
January 27, 2017
Stallergenes reports positive results for a p3 clinical study of allergic rhinitis in children
Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, has reported positive topline results for a phase 3 clinical…
January 27, 2017
BMS posts Q4 net profit, revenues driven by Opdivo sales up
Bristol-Myers Squib on Thursday posted fourth quarter net earnings of $1.1 billion, driven ly by increased sales of Opdivo and Eliquis.